CA-OPTIV-SECURITY
6.3.2019 16:07:03 CET | Business Wire | Press release
Most organizations conduct annual risk assessments, identify gaps, and receive recommendations for how to remediate those gaps. But many lack the resources to follow through on planning and operationalization. Based on strategies developed or assessments performed, many organizations know what to do but often not how to do it. Optiv Security , the world’s leading security solutions integrator, today announced its new Risk Transformation ServiceTM , an end-to-end solution that includes strategy execution.
Designed to enable clients around the world to better evaluate current risk against acceptable risk, Optiv’s Risk Transformation ServiceTM helps clients develop strategies that drive cohesive cybersecurity programs, execute on those strategies to mitigate enterprise risk, and achieve measurable outcomes. The service puts business strategy and risk at the heart of cyber decision-making with two distinct options:
- The Enterprise Risk Transformation Service TM helps organizations execute on risk transformation based on business objectives, results of an existing strategy or assessment, and a list of desired improvements or future mode of operation. This service includes program management, quality assurance and oversight over all or parts of a transformation or remediation initiative.
- The Quickstart Risk Transformation Service TM enables mid-sized organizations to get started with a risk-centric model for cybersecurity and aids them in the first steps of execution of their transformation roadmap. Optiv helps these clients set and execute a strategy, engaging with them from start to finish.
“Organizations today are adopting new risk and compliance principles to achieve business resilience,” said Dustin Owens, Optiv’s vice president, risk advisory. “As IT risk management evolves to more holistic operational risk management, it is being integrated into the fabric of organizations. This means that security teams are now a critical component to the overall business risk strategy.”
Owens continued, “As a result, adaptive, risk-based decision-making is becoming core to business agility and resilience, taking over from the antiquated check-the-box, compliance-based approach of the past. It’s high time for companies to embrace the risk revolution. They need to take a stance against the outside-in approach – which is predicated on continuously responding to legislative and regulatory requirements, specific threats, and other outside factors – and rewrite how they manage cybersecurity by proactively addressing all aspects of cybersecurity risk, including privacy and governance , cyber resilience, and risk optimization.”
Optiv’s new Risk Transformation ServiceTM is part of the company’s complete continuum of fully integrated cybersecurity risk services, which are focused on resolving three prevalent business issues:
- The need for risk governance – Optiv helps clients understand where critical assets are located, why they are important, how they are protected and who has access; and as these variables change, how their risk profile changes. This enables organizations to make security decisions based on risk so they can move faster, safely.
- Volume and velocity of change – Optiv allows clients to embrace the fast pace of digital transformation initiatives and deal with constant operational chaos simultaneously by helping them execute adaptive cyber resilience capabilities.
- Articulating security health to the business and board – Optiv provides security teams with everything they need to articulate risk and security performance in business terms by enabling them to effectively measure, monitor and report on security posture and align security to business objectives. This allows security teams to influence better decision-making and improve overall business health.
Please visit Optiv’s website to learn more about risk transformation or the company’s overarching approach to risk management .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn:
www.linkedin.com/company/optiv-inc
Facebook:
www.facebook.com/optivinc
YouTube:
www.youtube.com/c/OptivInc
Blog:
www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv helps clients plan, build and run successful cybersecurity programs that achieve business objectives through our depth and breadth of cybersecurity offerings, extensive capabilities and proven expertise in cybersecurity, integration and cyber operational services. Optiv maintains premium partnerships with more than 350 of the leading cybersecurity technology manufacturers. For more information, visit www.optiv.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005475/en/
Contact:
Brett Ater (913) 304-7683 Brett.ater@optiv.com or Jason Cook (816) 701-3374 Jason.cook@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
